ClinicalTrials.gg

Program

Pafolacianine

Also written as “CYTALUX (pafolacianine) injection”, “OTL38 for Injection” and “OTL38”.

Its studies are mostly in Ovarian Neoplasms · Lung Neoplasms, led by On Target Laboratories.

Furthest: phase 4, since Mar 9, 20263 company-led studies, 1 open or runningNext primary completion: May 28, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
On Target Laboratories31 open or runningphase 4since Mar 9, 2026Nov 18, 2014May 28, 2027phase 4 · NCT07469202

Also a collaborator on its studies: medelis-inc and synteracthcr.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2014First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT02317705 · 48 enrolled · United States
  2. Aug 5, 2016Phase 2 study in Lung NeoplasmsNCT02872701 · 100 enrolled · United States, Netherlands
  3. Mar 9, 2026Phase 4 study in Ovarian NeoplasmsNCT07469202 · 106 planned

Ahead

  1. May 28, 2027Primary completion: phase 4 study in Ovarian NeoplasmsNCT07469202

TargetBeta

NOC2L →read by rule
“Pafolacianine is a fluorescent imaging agent that targets folate receptors which are overexpressed in many cancers and is used with near infrared (NIR) imaging during surgery to identify tumor cells.”study text, by rule · the study

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07469202Ovarian Neoplasms4Not yet recruitingMay 28, 2027106
NCT02872701Lung Neoplasms · United States, Netherlands2CompletedOct 31, 2018100
NCT02317705Ovarian Neoplasms · United States2CompletedNov 201548

How it is read

Names in the registry

  • “CYTALUX (pafolacianine) injection”, 1 entry
  • “OTL38 for Injection”, 1 entry
  • “OTL38”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.